Crawford joins lobbying firm
This article was originally published in The Tan Sheet
Former FDA Commissioner Lester Crawford joined the lobbying firm Policy Directions in January as senior counsel. The government relations firm counts the Pharmaceutical Research & Manufacturers of America, the Biotechnology Industry Organization and several major pharmaceutical companies as clients. According to public disclosures, PhRMA paid Policy Directions $120,000 in 2005 to lobby Congress, HHS and FDA on importation, FDA regulation and user fees. Additionally, Merck and Genzyme each paid the firm $80,000 in 2005. According to the firm's website, it was involved in modifying the Controlled Substances Act, it helped garner support for the "Best Pharmaceuticals for Children Act" and "successfully achieved FDA advisory committee support for a product that had originally been voted down." Crawford's abrupt departure from FDA has been under review by the HHS Inspector General (1"The Tan Sheet" Sept. 26, 2005, p. 5)...
You may also be interested in...
Commissioner Von Eschenbach: NCI Director Named Acting Head Of FDA
National Cancer Institute Director Andrew von Eschenbach, MD, brings extensive scientific expertise and experience working with Congress as the head of a high-profile federal agency to the role of FDA commissioner
Affibody And UCB Eye Humira’s Weak Spot In Hidradenitis Suppurativa
The rival firms are advancing separate biologic candidates that target IL-17 in a bid to treat the more than 60% of hidradenitis suppurativa patients who remain uncontrolled on AbbVie’s Humira, with recent trial readouts showing promise.
Pharma Giants Urge Biotechs To Get In Touch As Early As Possible
Although money is too tight to mention for some biotechs, last year the value of preclinical partnerships actually went up and Switzerland’s big two pharma players are on the lookout for more.